From AHA abstract released today:

November 11, from 10:30 AM to 11:45 AM CST: "Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study."

"Enrollment of 2418 patients was completed on Mar 6, 2018. Baseline characteristics include: male sex 74.5%; mean age 61 (SD 9.5) years; median (interquartile range) LDL-C 65.0 (36) mg/dL, HDL-C 33.0 (7) mg/dL, HbA1c 7.3 (2.3) %, and blood pressure 129/76 mmHg; eGFR<60 ml/min 11%; treatment with atorvastatin (40/80mg) or rosuvastatin (20/40mg) 91.6%; dual anti-platelet therapy 85%; index ACS event MI 75% ; coronary revascularization for index ACS 78%; and median time from index ACS to randomization 34 days."